Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT05259319 | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)(IMMUNOs-SBRT) | unknown | Phase 1 | 92 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 |
| clinicaltrials |
| NCT06086574 | Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer(VIGILANCE) | unknown | — | 80 | University of ManchesterOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06086587 | Development and Application of Molecular Evaluation Instrument for Lung Cancer Diagnosis and Treatment | unknown | — | 500 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 17, 2023 | clinicaltrials |
| NCT06081270 | Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer(MUT-ONC) | unknown | — | 20 | University of Milano BicoccaOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06081777 | Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer(MRDinS3LC) | unknown | — | 65 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT04737382 | Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.(OSIRIS) | unknown | N/A | 200 | The Netherlands Cancer InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06065592 | Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms(CAT_PB) | unknown | Phase 1 | 500 | Lebanese UniversityOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06068088 | Dietary Practices and Locally Advanced Lung Cancer (LUNGDIET)(LUNGDIET) | unknown | — | 120 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 5, 2023 | clinicaltrials |
| NCT06065813 | Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer | unknown | Phase 2 | 20 | Northern Jiangsu People's HospitalOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04591431 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy(ROME) | unknown | Phase 2 | 400 | Fondazione per la Medicina PersonalizzataOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT05451173 | Combining ICI With SBRT or HypoFrx-RT for ES NSCLC | unknown | Phase 1 / Phase 2 | 83 | Alexander ChiOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT04726215 | Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer | unknown | Phase 2 | 50 | CellSight Technologies, Inc.INDUSTRY | 1 | Sep 29, 2023 | clinicaltrials |
| NCT05273047 | RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC(LungKG12Ci) | unknown | — | 458 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT05497973 | Psychosocial eHealth in Advanced Lung Cancer | unknown | N/A | 152 | Institut Català d'OncologiaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT06060964 | Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management(Breathe Easier) | unknown | Early Phase 1 | 24 | University of South CarolinaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04074993 | Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays | unknown | Phase 2 | 35 | JI-YOUN HANOTHER_GOV | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04364776 | Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC. | unknown | — | 100 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05128630 | Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.(DEDALUS) | unknown | Phase 2 | 45 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05452200 | Lung Cancer Screening Implementation Among Employees at Lyon Hospital(ILYAD) | unknown | N/A | 600 | Hospices Civils de LyonOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05728619 | HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 64 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05926336 | The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action | unknown | Phase 4 | 1,316 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05228496 | A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC | unknown | Phase 2 | 21 | Zhejiang Cancer HospitalOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05999214 | 99mTc-H7ND SPECT/CT Imaging in NSCLC | unknown | N/A | 150 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT06018688 | Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. | unknown | Phase 2 | 44 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Sep 21, 2023 | clinicaltrials |
| NCT05418660 | Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC(I-STOP) | unknown | — | 300 | University of Milano BicoccaOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT05992740 | Role of Bronchoscope in Diagnosis of Lung Cancer | unknown | N/A | 65 | Assiut UniversityOTHER | 0 | Sep 14, 2023 | clinicaltrials |
| NCT05518669 | mCBCT in Combination With ENB for the Diagnosis of PPNs | unknown | — | 109 | Shanghai Chest HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06031597 | Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy | unknown | Phase 3 | 105 | Zhejiang Cancer HospitalOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT03334864 | Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG) | unknown | — | 5,000 | Peking Union Medical College HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05338619 | A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy(PLATINUM) | unknown | Phase 2 | 77 | Sung Yong LeeOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06020989 | Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy(CHAMELEON) | unknown | Phase 2 | 129 | Yonsei UniversityOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06020352 | The Efficacy and Safety of KN046 Combined With Axitinib | unknown | Phase 2 / Phase 3 | 20 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05699213 | MRI and Biomarkers for Lung Nodules Detected During Lung Cancer Screening | unknown | — | 30 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05716815 | Prospective rAndomized sTudy efficaCy tHree-dimensional rEconstructions Segmentectomy(PATCHES) | unknown | N/A | 288 | Ospedale Centrale BolzanoOTHER | 0 | Aug 29, 2023 | clinicaltrials |
| NCT05994339 | Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer | unknown | Phase 2 / Phase 3 | 40 | Laibin People's HospitalOTHER | 0 | Aug 29, 2023 | clinicaltrials |
| NCT06014450 | Prophylactic Cranial Irradiation Versus Observation in Stage IV NSCLC Randomized Controlled Clinical Study | unknown | N/A | 144 | Guizhou Medical UniversityOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05869162 | Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI | unknown | Phase 2 | 153 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT06010277 | Folinic Acid for Prevention of Pemetrexed-induced Toxicity(FLEX) | unknown | Phase 4 | 50 | Amphia HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05892237 | CIETAI and Sequential Radiotherapy in Squamous Lung Cancer | unknown | Phase 2 | 50 | Dong WangOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05347628 | Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 91 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT06000358 | The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer(LUCACRIMUNO) | unknown | N/A | 120 | Lithuanian University of Health SciencesOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03215693 | X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib | unknown | Phase 2 | 152 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05991895 | Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer | unknown | — | 5,000 | Jinming YuOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05102214 | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 150 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05978401 | Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 152 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05975944 | Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05837598 | Adapting the Tumor Board Model for Mental Illness and Cancer | unknown | N/A | 30 | Massachusetts General HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05974007 | Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC(NeoR-World) | unknown | — | 1,500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05739006 | Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | unknown | Phase 1 | 131 | BiocadINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 19, 2023source: clinicaltrials